About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Scientist’s Breakthrough Test may Help Reduce Chemotherapy Trauma

by Medindia Content Team on October 8, 2007 at 3:40 PM
Font : A-A+

Scientist’s Breakthrough Test may Help Reduce Chemotherapy Trauma

A scientist from the University of New South Wales in Sydney has devised a technique to reduce the trauma of chemotherapy in people with cancer, raising hopes that patients' lives will be saved or extended.

Professor Philip Hogg, the director of the university's NSW Cancer Research Centre, says that his test uses a dye to determine whether cancer cells are being destroyed or not.

Advertisement

He says he has developed a family of molecules that attach themselves to dying or dead cancer cells, which enables doctors to determine whether a particular course of treatment is working within 24 hours of the first dose.

Currently, patients receiving chemotherapy or radiotherapy have to undergo a full cycle of treatment, which can take up to six months, before it can determined whether the tumour has been reduced or has grown.
Advertisement

Professor Hogg says the dye may prevent patients from the side effects in case their combination of cytotoxic drugs proves ineffective. He also says that new test can enable doctors to personalise treatment.

"Chemotherapy has three outcomes - the tumour is reduced, stays the same, or it grows and spreads - but we have no way of knowing which way things are going until the end of a cycle of treatment, or several cycles," the Sydney Morning Herald quoted him as saying.

"If, at the end of a cycle, we find out the tumour has not been reduced, the oncologist must prescribe a new combination of drugs, or a different treatment, and the patient starts again. This means patients go through a lot of trauma and many don't have the time to waste on ineffective therapies," he added.

According to Professor Hogg, patients would be injected with the dye within 24 to 48 hours after the first dose of chemotherapy or radiotherapy, after which a CT scan would be used to see dead or dying cancer cells.

He says that an oncologist can immediately change the treatment in case none of the cancer cells dies.

"This discovery stems from more than 10 years of research focused on the design of molecular probes to study cellular processes," he said. "We were working on another project when we found that these molecules attached to dead, cultured cells, so we decided to follow our noses and see where it took us. It is very exciting to be able to tailor treatment and to prevent people from the trauma of going through a chemotherapy cycle for months only to find out it didn't work," he added.

He said that the dye was expected to work on the cancers of lung, breast, colon and prostate. However, it would not be suitable for leukaemia.

The US pharmaceutical giant Covidien has bought the development rights in an undisclosed worldwide deal worth tens of millions of dollars in royalties to the university.

The firm hopes to have the dye on the market within five years. Clinical trials with it will begin within two years.

Source: ANI
LIN/C
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Trauma Care Chronic Lymphocytic Leukemia Hodgkins Lymphoma Non-Hodgkins Lymphoma Chemotherapy Chemotherapy Drugs Peritoneal Cancer Rhabdomyosarcoma Male Breast Cancer Tumor Lysis Syndrome 

Recommended Reading
Hodgkins Lymphoma - Chemotherapy
Proper treatment cures the majority of Hodgkin's lymphoma cases. However, 25% of patients remain ......
Combination of Tratuzumab and Chemotherapy Yields Better Results for Breast Cancer
combination treatment with the antibody trastuzumab and chemotherapy improves survival in women ......
Intraoperative Radiation Therapy – a New Step in Breast Cancer Treatment
A step forward for breast Cancer treatment comes in the form of Intraoperative radiation therapy. .....
New Adjuvant Breast Cancer Treatments Found Cost-effective
Two new studies have found that new adjuvant treatments for breast cancer are cost-effective at ......
Chemotherapy
‘Chemo’ means medicine or ‘drug’; ‘therapy’ means ‘treatment’. Chemotherapy refers to the use of cy...
Chemotherapy Drugs
Chemotherapy drugs perform like ‘magic bullets’ to destroy cancer cells in the body....
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is consider...
Hodgkins Lymphoma
Hodgkins lymphoma or Hodgkins disease has the distinction of being the first cancer to be cured by c...
Male Breast Cancer
Most cases of male breast cancer are diagnosed between the ages of 60 and 70 years. Treatment of mal...
Non-Hodgkins Lymphoma
Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of ....
Peritoneal Cancer
Peritoneal cancer is a rare cancer that develops in the peritoneum. Peritoneal cancers may be primar...
Rhabdomyosarcoma
Rhabdomyosarcoma is a rare type of cancer affecting the striated muscles. It mostly occurs in ......
Trauma Care
Accident and trauma care is an important public health challenge that requires immediate attention. ...
Tumor Lysis Syndrome
Tumor lysis syndrome is a collection of metabolic abnormalities due to the tumor cell lysis in patie...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use